Incidence and clinical course of immune checkpoint inhibitor-related cardiac adverse events: A descriptive study from the Middle East

Table 7 Diagnostic features, therapeutic interventions, and clinical outcomes in patients with post-immune checkpoint inhibitors cardiac complications (n = 14), n (%)/median (interquartile range)

Characteristic	Value
Median troponin-T level, ng/L	41 (20-534)
Median NT-proBNP, pg/mL	494 (373.5-3052)
Cardiac magnetic resonance imaging suggestive of myocarditis	1 (7.1)
Reduced LVEF	8 (57.1)
Medical management
Beta-blockers	8 (61.5)
ACEi/ARB/ARNI	6 (46.2)
Aspirin	5 (38.5)
Statin	4 (30.8)
Clopidogrel	3 (23.1)
SGLT2 inhibitors	3 (23.1)
Corticosteroids	2 (15.4)
Loop diuretics	2 (15.4)
Spironolactone	1 (7.7)
Anti-arrhythmias	1 (7.7)
Ivabradine	1 (7.7)
Hospitalized	7 (50)
ICU admission	2 (14.3)
ICI therapy discontinued	14 (100)
Mortality
In-hospital	4 (28.6)
Died after discharge	2 (14.3)
Permanent cardiac dysfunction	10 (71.4)
Resolution of cardiac toxicity	1 (7.1)

NT-proBNP: N-terminal pro-B-type natriuretic peptide; LVEF: Left ventricular ejection fraction; ACEi: Angiotensin converting enzyme inhibitors; ARB: Angiotensin II receptor blockers; ARNI: Angiotensin receptor neprilysin inhibitor; SGLT2: Sodium-glucose cotransporter 2; ICU: Intensive care unit; ICI: Immune checkpoint inhibitors.